ARCT Arcturus Therapeutics Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARCT

Price (delayed)

$6.82

Market cap

$193.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.83

Enterprise value

$2.15M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 15
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 30

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
Arcturus Therapeutics Holdings's debt has decreased by 50% YoY and by 5% QoQ
ARCT's quick ratio is up by 13% year-on-year but it is down by 4.8% since the previous quarter
The revenue has dropped by 62% year-on-year and by 33% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has shrunk by 62% YoY and by 33% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arcturusrx.com

Key stats

What are the main financial stats of ARCT

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-0.87%
1 week
-5.67%
1 month
-13.89%
1 year
-48.84%
YTD
11.26%
QTD
-11.66%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$54.71M
Gross profit
$54.71M
Operating income
-$88.37M
Net income
-$78.67M
Gross margin
100%
Net margin
-143.8%
Arcturus Therapeutics Holdings's operating margin has shrunk by 183% YoY and by 74% QoQ
Arcturus Therapeutics Holdings's net margin has shrunk by 79% QoQ
The revenue has dropped by 62% year-on-year and by 33% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has shrunk by 62% YoY and by 33% QoQ

Price vs fundamentals

How does ARCT's price correlate with its fundamentals

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
ARCT P/E details
P/E
N/A
P/B
1.01
P/S
3.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.04
The company's EPS fell by 18% QoQ and by 12% YoY
ARCT's P/B is 59% lower than its 5-year quarterly average of 2.5 and 27% lower than its last 4 quarters average of 1.4
ARCT's equity is down by 18% year-on-year and by 11% since the previous quarter
ARCT's price to sales (P/S) is 84% lower than its 5-year quarterly average of 21.8 but 2% higher than its last 4 quarters average of 3.5
The revenue has dropped by 62% year-on-year and by 33% since the previous quarter

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The company's return on sales has shrunk by 79% QoQ
Arcturus Therapeutics Holdings's ROIC has plunged by 68% from the previous quarter and by 20% YoY
The ROA has decreased by 49% YoY and by 29% QoQ
The company's return on equity fell by 34% YoY and by 26% QoQ

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total liabilities has decreased by 45% YoY and by 5% QoQ
Arcturus Therapeutics Holdings's total assets has decreased by 26% YoY and by 9% QoQ
Arcturus Therapeutics Holdings's debt is 90% lower than its equity
Arcturus Therapeutics Holdings's debt has decreased by 50% YoY and by 5% QoQ
The debt to equity has decreased by 41% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.